Listing 3 - Actual negotiations

Indication:

In neoadjuvant setting for resectable stage III melanoma.

Indication:

In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy.

Indication:

As monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors

Indication:

As monotherapy for the adjuvant treatment of adult patients with Stage IB (T2a 4 cm), II, or IIIA NSCLC, and with PD-L1 tumor proportion score (TPS) less than 50% who have undergone complete resection and platinum-based chemotherapy.

Indication:

COVID-19 in hospitalized patients

Indication:

COVID-19 in non-hospitalized patients

Indication:

Psoriatic Arthritis

Indication:

Ankylosing spondylitis

Indication:

Hodgkin's Lymphoma

Indication:

Breast cancer, locally advanced or metastatic (HR-positive, HER2-negative)